the aid library

LIST OPTIONS

Filter

20300

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot... more

Download (308)

View PDF (461)

European Drug Report 2019: trends and developments.

European Monitoring Centre for Drugs and Drug Addiction European Union (2019) C1

The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2019 European Drug ... more

Download (188)

View PDF (377)

Plan de respuesta de emergencia Colombia - COVID -19

Reliefweb; OCHA Services; Acción contra el Hambre España (2020) C2

Accessed: 01.05.2020 El 11 de marzo de 2020 la OMS (Organización Mundial de la salud) ha declarado el CORONAVIRUS - COVID 19 como una pandemia mundial después que el número de afectados fuera de China se haya multiplicado por 13 en dos semanas y el de los demás países se haya triplicado en e... more

Download (397)

View PDF (271)

Compétences essentielles pour la pratique du métier de sage-femme

International Confederation of Midwives (ICM) (2019) C1

Les documents d’orientation sont révisés en fonction de l’évolution permanente de la recherche. Les énoncés des compétences essentielles de l’ICM sont également évalués et modifiés au fur et à mesure que des preuves pertinentes concernant les soins de santé sexuelle, génésique, ... more

Download (486)

View PDF (518)

Introducing and scaling up testing for human papillomavirus as part of a comprehensive programme for prevention and control of cervical cancer

World Health Organization WHO (2020) C_WHO

This guidance is intended to be used by programme managers following the decision to introduce human papillomavirus (HPV) virological testing as a screening assay in their national cervical cancer prevention and control programme. The guidance includes a step-by-step process to be followed after the... more

Download (484)

View PDF (339)

National Guidelines for Integrated Diseases Surveillance and Response Uganda

World Health Organization WHO, Regional Office of Africa; Ministry of Health Uganda (2021) C_WHO

3rd edition. In 2001, Uganda adapted the Integrated Disease Surveillance and Response (IDSR) developed by World Health Organization (WHO) for member states in African region. The Ministry of Health has been implementing the IDSR strategy since then with success across the country. This strategy prov... more

External Link

Financing Global Health 2014: Shifts in Funding as the MDG Era Closes

Institute for Health Metrics and Evaluation (2015) CC

Financing Global Health 2014 is the sixth edition of this annually produced report on global health financing. As in previous years, this report captures trends in development assistance for health (DAH) and government health expenditure (GHE). Health financing is one of IHME’s core research areas... more

External Link

Mycetoma: epidemiology, treatment challenges, and progress

Taha, H.; Fahal, A.; Van de Sande, W. Dovepress open access to scientific and medical research (2015) CC

Mycetoma is a specific chronic, granulomatous, inflammatory disease. It usually involves the subcutaneous tissue, most probably after traumatic inoculation of the causative organism. It has a prolonged, progressive, and indolent course, and, if untreated, it ultimately leads to destruction of the de... more

Download (256)

View PDF (268)

Adolescent Girls in Disaster & Conflict: Interventions for Improving Access to Sexual and Reproductive Health Services

S. Guthridge-Gould UNFPA (United Nations Population Fund) (2016) C2

Download (843)

View PDF (1857)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (1473)

View PDF (1771)

Basic Epidemiology

Bonita, R.; R.Beaglehole, and T. Kjellström World Health Organization WHO (2006) C_WHO

2nd edition

Download (272)

View PDF (282)

TB Advocacy Guide - For People who use Drugs

hit.org.uk; INPUD (2019) C2

Accessed: 19.10.2019

Download (437)

View PDF (660)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (2427)

View PDF (2766)

WHO-WPR Emergency Response Manual

World Health Organization, Western Pacific Office (2003)

Guidelines for WHO Representatives and Country Offices in the Western Pacific Region

Download (555)

View PDF (863)

Toolkit on disability for AFRICA: INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) AND DISABILITY

United Nations Division for Social Policy Development (DSPD) & United Nations Department of Economic and Social Affairs (DESA) (2016) C1

Module 12

Download (337)

View PDF (511)

Global clinical data platform for severe acute hepatitis of unknown aetiology in children case report form (CRF)

World Health Organization WHO (2022) C_WHO

Multiple countries are reporting severe acute cases of hepatitis of unknown aetiology in children, in several regions of the world. WHO has developed this clinical case report form (CRF) to support and facilitate reporting of anonymized, patient-level data of acute hepatitis of unknown aetiology.